Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET
October 14 2021 - 8:00AM
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical
company focused on developing and commercializing differentiated
products that address patients’ unmet needs and solve therapeutic
problems, announced today that it will report results for third
quarter ended September 30, 2021 and provide an update on recent
developments in its business after market close on Tuesday,
November 2, 2021.
Management will host a conference call for
investors at 8:00 a.m. ET on Wednesday, November 3, 2021. The
conference call can be accessed by dialing (866) 417-5886 from the
U.S. and (409) 217-8235 internationally, followed by the conference
ID: 4285256.
There will also be a simultaneous, live webcast
available on the Investors section of the Company’s website at
https://investors.aquestive.com/events-and-presentations. The
webcast will be archived for 30 days.
About Aquestive
TherapeuticsAquestive Therapeutics is a pharmaceutical
company that applies innovative technology to solve therapeutic
problems and improve medicines for patients. The Company has
commercialized one internally-developed proprietary product to
date, Sympazan® (clobazam) oral film, has a commercial proprietary
product pipeline focused on the treatment of diseases of the
central nervous system, or CNS, and other unmet needs, and is
developing orally administered complex molecules to provide
alternatives to invasively administered standard of care therapies.
The Company also collaborates with other pharmaceutical companies
to bring new molecules to market using proprietary, best-in-class
technologies, like PharmFilm®, and has proven capabilities for drug
development and commercialization.
Forward-Looking
StatementCertain statements in this press release include
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,”
“will,” or the negative of those terms, and similar expressions,
are intended to identify forward-looking statements. These
forward-looking statements include, but are not limited to,
statements regarding the advancement of our product candidate
Libervant™ (diazepam) Buccal Film and other product candidates
through the regulatory and development pipeline and business
strategies, market opportunities, and other statements that are not
historical facts. These forward-looking statements are subject to
the uncertain impact of the COVID-19 global pandemic on our
business including with respect to our clinical trials including
site initiation, patient enrollment and timing and adequacy of
clinical trials; on regulatory submissions and regulatory reviews
and approvals of our product candidates; pharmaceutical ingredient
and other raw materials supply chain, manufacture, and
distribution; sale of and demand for our products; our liquidity
and availability of capital resources; customer demand for our
products and services; customers’ ability to pay for goods and
services; and ongoing availability of an appropriate labor force
and skilled professionals. Given these uncertainties, the Company
is unable to provide assurance that operations can be maintained as
planned prior to the COVID-19 pandemic.
These forward-looking statements are based on
our current expectations and beliefs and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
Such risks and uncertainties include, but are not limited to, risks
associated with the Company's development work, including any
delays or changes to the timing, cost and success of our product
development activities and clinical trials; risk of delays in FDA
approval of Libervant and our other drug candidates or failure to
receive approval; ability to address the concerns identified in the
FDA’s Complete Response Letter dated September 25, 2020 regarding
the New Drug Application for Libervant; risk of our ability to
demonstrate to the FDA “clinical superiority” within the meaning of
the FDA regulations of Libervant relative to FDA-approved diazepam
rectal gel and nasal spray products including by establishing a
major contribution to patient care within the meaning of FDA
regulations relative to the approved products as well as risks
related to other potential pathways or positions which are or may
in the future be advanced to the FDA to overcome the seven year
orphan drug exclusivity granted by the FDA for the approved nasal
spray product of a competitor in the U.S. and there can be no
assurance that we will be successful; risk that a competitor
obtains FDA orphan drug exclusivity for a product with the same
active moiety as any of our other drug products for which we are
seeking FDA approval and that such earlier approved competitor
orphan drug blocks such other product candidates in the U.S. for
seven years for the same indication; risk in obtaining market
access for other reasons; risk inherent in commercializing a new
product (including technology risks, financial risks, market risks
and implementation risks and regulatory limitations); risk of
development of our sales and marketing capabilities; risk of legal
costs associated with and the outcome of our patent litigation
challenging third party at risk generic sale of our proprietary
products; risk of sufficient capital and cash resources, including
access to available debt and equity financing and revenues from
operations, to satisfy all of our short-term and longer term cash
requirements and other cash needs, at the times and in the amounts
needed; risk of failure to satisfy all financial and other debt
covenants and of any default; our and our competitors’ orphan drug
approval and resulting drug exclusivity for our products or
products of our competitors; short-term and long-term liquidity and
cash requirements, cash funding and cash burn; risk related to
government claims against Indivior for which we license,
manufacture and sell Suboxone® and which accounts for the
substantial part of our current operating revenues; risks related
to the outsourcing of certain marketing and other operational and
staff functions to third parties; risk of the rate and degree of
market acceptance of our product and product candidates; the
success of any competing products, including generics; risk of the
size and growth of our product markets; risks of compliance with
all FDA and other governmental and customer requirements for our
manufacturing facilities; risks associated with intellectual
property rights and infringement claims relating to the Company's
products; risk of unexpected patent developments; the impact of
existing and future legislation and regulatory provisions on
product exclusivity; legislation or regulatory actions affecting
pharmaceutical product pricing, reimbursement or access; claims and
risks that may arise regarding the safety or efficacy of the
Company's products and product candidates; risk of loss of
significant customers; risks related to legal proceedings,
including patent infringement, investigative and antitrust
litigation matters; changes in government laws and regulations;
risk of product recalls and withdrawals; uncertainties related to
general economic, political, business, industry, regulatory and
market conditions and other unusual items; and other uncertainties
affecting the Company described in the “Risk Factors” section and
in other sections included in our Annual Report on Form 10 K, in
our Quarterly Reports on Form 10-Q, and in our Current Reports on
Form 8-K filed with the Securities Exchange Commission (SEC). Given
those uncertainties, you should not place undue reliance on these
forward-looking statements, which speak only as of the date made.
All subsequent forward-looking statements attributable to us or any
person acting on our behalf are expressly qualified in their
entirety by this cautionary statement. The Company assumes no
obligation to update forward-looking statements or outlook or
guidance after the date of this press release whether as a result
of new information, future events or otherwise, except as may be
required by applicable law.
PharmFilm®, Sympazan® and the Aquestive logo are
registered trademarks of Aquestive Therapeutics, Inc. All other
registered trademarks referenced herein are the property of their
respective owners.
Investor Inquiries Westwicke, an ICR Company
Stephanie Carrington
stephanie.carrington@westwicke.com 646-277-1282
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Sep 2023 to Sep 2024